Drug Trial Radar · NCT04818372
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
87
Planned (sponsor's estimate)
Start
Apr 26, 2021
Primary completion
Jan 2023
Study completion Apr 2023
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CM313. The dose escalation part will determine the MTD of CM313 in subjects with relapsed and/or refractory multiple myeloma (RRMM) or lymphoma based on a modified 3+3 dose escalation design (an accelerated dose titration design followed by traditional 3+3 dose escalation design). The dose expansion part includes two cohorts. Cohort 1 will evaluate the safety and preliminary anti-tumor activity of CM313 in combination with Dexamethasone in subjects with RRMM. Cohort 2 will evaluate the safety and preliminary anti-tumor activity of CM313 in combination with Rd regimen (Lenalidomide/Dexamethasone) in subjects with RRMM or newly diagnosed MM (NDMM).
Conditions
- Multiple Myeloma
- Lymphoma
Interventions
CM313-Dose escalationDrug
Subjects will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.
CM313Drug
Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.
DexamethasoneDrug
dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
LenalidomideDrug
25 mg/day lenalidomide 21 of 28 days cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose escalation: Number of Participants with a Dose-Limiting Toxicity (DLT)Time frame: Up to 21 days after the first dose
- Dose escalation and Dose expansion: Incidence, severity, and outcome of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0Time frame: Up to 30 days after the last dose of CM313 or until the start of subsequent anticancer therapy, if earlier
- Dose expansion: To evaluate the activity of CM313 in combination with Rd/Dexamethasone as assessed by overall response rate (ORR) in RRMM patientsTime frame: Up to 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chao-Yang Hospital, Capital Medical University (West Branch)
Beijing, Beijing Municipality, China · Recruiting
Beijing Chao-Yang Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.